GVIRF is the central forum for research related to the Global Vaccine Action Plan (GVAP) and its successor, the Immunization Agenda 2030 (IA2030).

GVIRF is the only global meeting that brings together the entire Vaccine and Immunization Research community, from basic immunology to implementation research, and from low to high income countries.

GVIRF will:

  1. Track progressin vaccine research and development
  2. Identify gapsopportunities and actions to maximize the benefit of immunization
  3. Foster networking and collaboration to accelerate progress
  4. Support implementation of Immunization Agenda 2030

GVIRF will be:

Influential: Featuring high level keynotes and speakers from the forefront of immunization research
Timely: Reviewing progress in vaccines for COVID-19
Balanced: Discussing COVID-19 in context of overall immunization and relationship with other diseases
Equity-oriented: Aiming to foster global participation and address global needs

To enable active participation regardless of time zone, GVIRF 2021 will be held twice each day. The first block is for participants closer to the prime meridian (UTC +0). The second block is for participants closer to the international date line (UTC +12). Both blocks will have the same content. Please attend the sessions that work best for you.

GVIRF is hosted every two years by World Health Organization, the US National Institutes of Health, and the Bill & Melinda Gates Foundation.

For information on previous forums, please click here

Meeting videos and presentations will be posted to the TechNet Resource Library as they become available. 

To help us improve future GVIRFs, please complete our survey


For a more detailed agenda – please click here

Day 1

Block 1: Feb 22 14.00-17.30 CET
Block 2: Feb 23 09.00-12.30 KST


Anthony Fauci, Director, NIAID/NIH
With Lee Hall, NIAID/NIH

Day 2

Block 1: Feb 23 14.00-17.30 CET
Block 2: Feb 24 09.00-12.30 KST


Bill Gates, Co-chair, Bill & Melinda Gates Foundation
Anuradha Gupta, Deputy CEO, Gavi, the Vaccine Alliance

Day 3

Block 1: Feb 24 14.00-17.30 CET
Block 2: Feb 25 09.00-12.30 KST


Soumya Swaminathan, Chief Scientist, WHO

Plenary 1: Epidemic and Pandemic Preparedness and Response

George F. Gao, China CDC
Barney Graham, NIAID/NIH
Ana Maria Henao Restrepo, WHO
Jerome Kim, IVI
Helen Rees, WRHI
Melanie Saville, CEPI
Debra Yeskey, CEPI

Plenary 2: HIV, TB & Malaria Vaccine R&D Update

Norman Baylor, Biologics Consulting
Linda-Gail Bekker, U. of Cape Town
Graham Brown, U. of Melbourne​
Ann Ginsberg, BMGF
James Kublin, Fred Hutchinson CRC ​
Sodiomon B. Sirima, Groupe de Recherche Action en Santé
Lucky Slamet, Badam Pom

Plenary 3: Shaping the Future: Equitable Access for All

Daniel Feikin, WHO
Richard Hatchett, CEPI
Gagandeep Kang, CMC Vellore
Kim Mulholland, MCRI
Robin Nandy, UNICEF
Hanna Nohynek, Finnish Inst. for Health and Welfare
Katherine O’Brien, WHO
Samir Sodha, WHO
Collins Tabu, Ministry of Health, Kenya
Chris Wolff, BMGF

Concurrent Workshops
W1: Innovations in Vaccine Manufacturing

Antu Dey, IAVI
Jian Dong, WuXi Vaccines
Rajat Goyal, IAVI
Ahd Hamidi, Batavia Biosciences
Harish Iyer, BMGF
Casey Selwyn, BMGF
Anant Shah, Merck

Concurrent Workshops
W4: Controlled Human Infection Models

Norman Baylor, Biologics Consulting
Chris Chiu, Imperial College London
Gagandeep Kang, CMC Vellore
Melissa Kapulu, KEMRI-WT
Mike Levine, U. Maryland School of Medicine
Andrew Pollard, U. Oxford
Jetsumon Prachumsri, Mahidol U.

Concurrent Workshops
W7: Immune Responses over the Life Course

Galit Alter,  Ragon Institute
Martin Friede, WHO
Shirin Heidari, WHO
Tobias Kollmann, Telethon Kids Institute
Anis Larbi, Beckman Coulter
Janet McElhaney, Health Sciences North
Lois Privor-Dumm, John Hopkins IVAC
Ajoke Sobanjo-ter Meulen, BMGF
Sing Sing Way, CCHMC

W2: Emerging Platforms

Nathalie Garcon, BIOASTER
Sarah Gilbert, U. of Oxford
Florian Krammer, Mt. Sinai
Christian Mandl, Vaccines, Viral Vectors
Lynda Stuart, BMGF
Kanta Subbarao, WHO Collaborating Centre for Influenza

W5: New & Improved Vaccines on the Horizon

Ananda Bandyopadhyay, BMGF
Robert Bergquist, Geospatial Health
Peter Dull, BMGF
Aimée Kreimer, NCI/NIH
Kathleen Neuzil, CVD
Sushant Sahastrabuddhe, IVI

W8: Prioritization for Vaccine R&D

Bill Hausdorff, PATH
Peter Hotez, Baylor College of Medicine
Hun Kim, SK Bioscience
Jerome Kim, IVI
Younbeen Kim, RIGHT Fund
Morena Makhoana, Biovac
Jo Mulligan, UK FCDO
BT Slingsby, Catalys Pacific
Hiro Suzuki, MHLW JP
Rajeev Venkayya, Takeda
Margo Warren, Access to Medicine

W3: Innovation in Vaccination

Jon Abramson, Wake Forest
Alejandro Cravioto, UNAM
Matthew Downham, CEPI
David Durrheim, U. Newcastle
Suresh Jadhav, Serum Institute of India
Jim Janimak, GlaxoSmithKline
Gangadeep Kang, CMC Vellore
Bernhards Ogutu, KEMRI
Jim Robinson, CEPI
Marcel Tanner, STPHI
Fred Were, U. Nairobi
Darin Zehrung, PATH

W6: Policy Inputs, Decision for Development

Fred Binka, University of Health and Allied Sciences, Ho Ghana
Joshua Chu, CHAI
Alejandro Cravioto, UNAM
Brigitte Giersing, WHO
Ian Hudson, BMGF
David Kaslow, PATH
Deepali Patel, Gavi
Sai Prasad, Bharat Biotech International
Rino Rappuoli, GSK Vaccines

W9: Building and Sustaining Uptake

Simone Carter, UNICEF
Julie Leask, U. Sydney
Lisa Menning, WHO
Anna Lisa Ong-Lim, U. Philippines
Lucky Slamet, Badam Pom

For global participation, all sessions will be held twice.

Block 1 will be held February 22-24, 2021 from 14.00 – 17.30 Central European Time (CET) each day

Block 2 will be held February 23-25, 2021 from 09.00 – 12.30 Korean Standard Time (KST) each day


Is there a cost to attend?

The GVIRF is free to all participants.

Who can attend?

Researchers, practitioners, and students in vaccines and immunization.

What languages will be available?

GVIRF will be conducted in English.

Are both blocks the same?

Both blocks will feature the same presentations. Because of time differences, discussion panels may have different speakers. See the Detailed Agenda for each block to find out who will be speaking in each session.

Will the proceedings be available online?

Videos of sessions will be posted to the TechNet Resource Library as they become available.

Contact Us